#ESMO26 Exploratory ctDNA findings from phase III KEYNOTE-B15, comparing perioperative EV+pembrolizumab vs cisplatin/gemcitabine.

Key findings:
📌Presurgical ctDNA clearance: 82.1% vs 66.7%
📌24-month EFS after ctDNA clearance: 81.1% vs 63.2%
📌Persistent ctDNA positivity: 24-month EFS only ~33–35%
📌Postsurgical ctDNA positivity: Only 10% event-free at 24 months in either arm
📌Presurgical ctDNA-negative patients: pCR 72.4% vs 43.7%
@UroToday @myESMO